AstraZeneca: Tagrisso Drug Trial Shows Better than Chemotherapy for Some Patients
December 06 2016 - 5:25AM
Dow Jones News
LONDON--AstraZeneca PLC (AZN) said Tuesday that the first
randomized Phase III trial of its Tagrisso drug had demonstrated
better results than chemotherapy for some types of lung cancer.
The results showed the drug had the potential to replace
chemotherapy as the standard treatment for certain patients, the
pharmaceutical giant said.
Tagrisso is a once-daily tablet approved in the European Union,
the U.S., Japan and Canada and a number of other countries as the
first treatment for patients with certain types of lung cancer.
AstraZeneca shares at 0940 GMT were down 20 pence, or 0.5%, at
40.14 pounds($42.73), valuing the company at GBP50.77 billion.
-Write to Razak Musah Baba at razak.baba@wsj.com
(END) Dow Jones Newswires
December 06, 2016 05:10 ET (10:10 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
